NASDAQ · Key Statistics

UroGen Pharma Ltd. (URGN) P/E Ratio, ROE & Key Statistics

$29.87 NASDAQ: URGN Market Cap $1.47B

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for UroGen Pharma Ltd. (URGN), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-22.63
P/B ratioShare price divided by book value per share.-12.06
P/S ratioMarket value divided by annual revenue.5.85
PEG ratioP/E divided by the earnings growth rate.-0.20
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.-39.51
EV / RevenueEnterprise value against annual revenue.6.30
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-4.86%
Free cash flow yieldFree cash flow as a percentage of market value.-9.01%

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.91.41%
Operating marginRevenue left after operating costs.-12.36%
Net marginRevenue left after every cost, including tax and interest.-26.27%
Return on equityProfit as a percentage of shareholders’ equity.53.97%
Return on assetsProfit as a percentage of total assets.-24.18%
Return on capital employedOperating profit against the capital the business uses.-15.64%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.3.40
Quick ratioThe same, excluding inventory.3.06
Cash ratioCash alone against current liabilities.2.41
Debt to equityTotal borrowings against shareholders’ equity.-1.57
Debt to assetsTotal borrowings against total assets.0.64
Interest coverageHow many times operating profit covers the interest bill.-0.98

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$3.19
Market capitalisationShare price times shares outstanding.$1.47B
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$1.58B
EmployeesReported headcount.234

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

UroGen Pharma Ltd. (URGN) statistics — frequently asked questions

What is UroGen Pharma Ltd.'s P/E ratio?

UroGen Pharma Ltd. (URGN) trades on a price-to-earnings ratio of -22.63. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is UroGen Pharma Ltd.'s return on equity?

UroGen Pharma Ltd. (URGN) reports a return on equity of 53.97%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does UroGen Pharma Ltd. carry?

UroGen Pharma Ltd. (URGN) has a debt-to-equity ratio of -1.57, which compares total borrowings with shareholders' equity.

What is UroGen Pharma Ltd.'s profit margin?

UroGen Pharma Ltd. (URGN) keeps -26.27% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Biotechnology stocks

VRTX P/E 34.56REGN P/E 19.22MRNA ROE -37.62%RVMD ROE -91.93%ROIV ROE -6.12%INSM ROE -82.75%UTHR P/E 21.31INCY P/E 55.62ALNY P/E 36.02ASND P/E 17.60All Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.